RxDoctor Payments Data

Scott Rinesmith, MD

Internal Medicine · Lima, OHNPI 1790837433

Payments from drug & device makers

$64,233in general payments, 2019–2025

Across 820 payments — averaging $78.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$52K
  • AbbVie$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • UCB Biosciences Inc.$2K
  • Johnson & Johnson$808
  • Gilead$475
  • plus $5K from 40 others

What the payments were for

  • Speaking & faculty fees$1501%
  • Food & beverage$12,67998%
  • Education$1181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$64,233 in reported general payments places this provider in the 95th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$264,947
Medicare patients
462
Services billed
8,117

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin12$42,579
Mesalamine28$10,394
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates125$8,050
LinzessLinaclotide12$6,837
Colestipol Hcl35$4,525
Sucralfate235$4,257
Pantoprazole Sodium186$2,290
Lansoprazole14$2,263
Omeprazole236$2,030
Esomeprazole Magnesium18$1,238
Sulfasalazine DrSulfasalazine13$858
Lactulose22$647
Dicyclomine Hcl26$607
Sulfasalazine14$513
Famotidine49$451

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$1,762$42,57912 claims
AbbVieLinzess$3,192$6,83712 claims
SandozLansoprazole$16$2,26314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Lima

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →